pfizer 3sbio - Search News

Order byBest matchMost fresh

News

Pfizer makes a $6 billion run into a new cancer drug race

· 1d · on MSN

Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Continue reading

· 1d · on MSN

Pfizer Licenses 3SBio Cancer Drug for Record $1.2 Billion

· 1d · on MSN

Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China

Fierce Biotech1d

Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific, joining red-hot race with BioNTech, Merck

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

Pfizer Puts $6B on the Line for 3SBio’s PD-1/VEGF Antibody

The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results